Background The management of bilateral intracranial vertebral artery dissecting aneurysms (IVADAs) is controversial, and requires the development of endovascular treatment modalities and principles. We aim to investigate the endovascular treatment strategy and outcomes of bilateral IVADAs.
Methods We identified all bilateral IVADAs at a high-volume neurointerventional centre over a 10-year period (from January 2009 to December 2018). Radiographic and clinical data were recorded, and a treatment algorithm was derived.
Results Twenty-seven patients with bilateral IVADAs (54 IVADAs in total, 51 unruptured, 3 ruptured) were diagnosed. Four patients (14.8%) received single-stage endovascular treatment, 12 patients (44.4%) with staged endovascular treatment and 11 patients (40.8%) with unilateral endovascular treatment of bilateral IVADAs. Thirty-six IVADAs (85.7%) have complete obliteration at the follow-up angiography. Two of three ruptured IVADAs with stent-assisted coiling recanalised, and had further recoiling. Three patients (11.1%) have intraprocedural or postprocedural complications (two in single-stage and one in staged). Twenty-five patients (92.6%) had a favourable clinical outcome, and two patients (7.4%, all in single-stage) showed an unfavourable clinical outcome at follow-up. For the patients with unilateral reconstructive endovascular treatment, the contralateral untreated IVADAs were stable and had no growth or ruptured during follow-up period. None of all IVADAs had rebleeding during the clinical follow-up.
Conclusions Endovascular treatment can be performed in bilateral IVADAs with high technical success, high complete obliteration rates and acceptable morbidity/mortality. Contralateral IVADAs had low rates of aneurysm growth and haemorrhage when treated in a staged/delayed fashion.
- flow diverter
This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
Statistics from Altmetric.com
The incidence of intracranial vertebral artery dissecting aneurysms (IVADAs) in the general population is very low at 0.001%–0.0015%,1 but associated risks of morbidity, mortality and rebleeding are high.2–4 Bilateral IVADAs account for less than 10% of all IVADAs, but their management is more complex and challenging.5–9 Endovascular treatment has emerged as a major therapeutic option for IVADAs, with successful results reported for staged bilateral vertebral artery (VA) occlusion of bilateral IVADAs;10 however, bilateral VA occlusion is not tolerated in many patients. Unilateral trapping or bilateral parent artery reconstructive therapy has been used to treat such intolerant patients. However, the occlusion of one VA may cause increased flow in the contralateral VA, with associated haemodynamic stress and possible contralateral aneurysmal rupture or recanalisation.6 8 9 Because of the limited number of bilateral IVADA cases reported to date, clinicians are accustomed to treating these pathologies based on personal or institutional experience, and consensus on how to treat bilateral IVADAs has not yet been reached. In this article, we detail our experience of bilateral IVADAs and propose an endovascular treatment protocol, which aims to achieve a more effective treatment of the condition.
All medical data were reviewed retrospectively for diagnostic purposes.
Patient selection and study population
Between January 2009 and December 2018, we reviewed clinical and radiologic data from our aneurysm database. A total of 8176 patients were referred to our department of interventional neuroradiology for endovascular treatment of a cerebral aneurysm. We identified 712 patients with 747 IVADAs; bilateral IVADAs had an incidence of 0.33% in all IVADAs patients at our centre. All patients included in this study met the following inclusion criteria: (1) bilateral IVADAs confirmed by digital subtraction angiography (DSA), CT angiography (CTA) or MR angiography (MRA); (2) the aneurysm in the patient was treated using an endovascular approach. The exclusion criteria included (1) a history of trauma or iatrogenic injury; (2) the presence of fibromuscular dysplasia; (3) the absence of any clinical follow-up. Ultimately, 27 patients with 54 IVADAs were identified. We collected information on patient demographics (age, sex and clinical history); rupture and configuration of IVADAs; endovascular treatment selected; treatment complications and angiographic and clinical follow-up outcomes.
Endovascular treatment strategy
In our centre, two types of endovascular methods were used for treating IVADA patients, namely internal trapping and stent reconstructive techniques (stenting alone, stent-assisted coiling (SAC) techniques and flow diversion). The most important factors for selecting the treatment methods were the anatomic factors of the parent artery, including the involvement of the posterior inferior cerebellar artery (PICA) origin, the dominance of the affected VA and the sufficiency of the collateral blood supply. First, bilateral IVADA patients were classified into ruptured and unruptured, according to CT imaging data and patient symptoms. For patients with subarachnoid haemorrhage (SAH), one-stage treatment of bilateral IVADAs was performed for the patients whom the ruptured side was not confirmed. In contrast, a staged treatment was performed for the patients whom the ruptured side was confirmed. For patients with ruptured IVADAs, internal trapping was chosen as the treatment for the IVADA which was non-dominant or codominant, and which did not involve the PICA origin. The IVADA containing the dominant VA or involving the PICA origin was treated with stent reconstructive techniques. For the confirmed contralateral unruptured IVADAs with high ruptured risk, a staged treatment was performed 1 month later. For the unruptured patients, detailed image evaluation before treatment was performed, and staged endovascular treatment was chosen. Cases of IVADA with high rupture risk factors were treated first, such as aneurysms with dominant VA, complex aneurysms, aneurysm wall enhancement. If high rupture risk for bilateral IVADAs, the treatment of the contralateral IVADA was performed about 1 month later, otherwise, conservative treatment was considered. We optimised our management of bilateral IVADAs gradually after accumulating our experience, based on our previous work, we propose an endovascular treatment protocol for bilateral IVADAs during endovascular treatment (figure 1). For antiplatelet therapy before treatment, a loading dose of dual antiplatelet medication (300 mg aspirin and 300 mg clopidogrel) was given to patients with a ruptured IVADA who chose stent reconstructive techniques, while a standard antiplatelet regimen (100 mg aspirin and 75 mg clopidogrel; daily, from 5 days before the operation) was chosen for the unruptured patients.
All procedures were performed under general anaesthesia, and full procedural heparinization was used to achieve a targeted activated clotting time ranging from 250 to 300 s. Two catheters were used to deliver the coils for internal trapping, with the interlocking of the coils preventing coil migration during the procedure. For reconstructive treatment, we inserted the guiding catheter into the VA inferior to the atlas. For traditional stent alone technique, one or two self-expanding stents (Neuroform, Boston Scientific; Enterprise, Codman Neurovascular; Solitaire AB, ev3; or LVIS, MicroVention) were inserted, covering the entire segment of the dissecting aneurysm. For SAC, the stent delivery catheter was placed at the portion distal to the dissection, and a microcatheter was superselected to the IVADA. After filling two to three coils, the stent was released. For flow diversion, we adopted a triaxial supporting system to access the aneurysm, with the Pipeline Embolization Device (PED; Medtronic) introduced through a Marksman microcatheter. PED were delivered to reconstruct the parent artery in a satisfactory position, and then deployed. After the traditional stent procedure, 75 mg clopidogrel was administered every day for 6 weeks and 100 mg aspirin was administered each day for 6 months. After flow diversion, clopidogrel treatment was prolonged to 3 months, and aspirin prolonged to at least 1 year.
Follow-up angiographic examination was performed with a conventional DSA or CTA scan at 3 months. The patient was followed up with an MRA scan annually. Patient outcome was measured using the modified Rankin Scale (mRS) score through neurologic examination at follow-up visits, and assess the neurological status of the patient during a telephone interview. The results were categorised into favourable outcomes (mRS, 0–2) and unfavourable outcomes (mRS, 3–6) based on the last clinical follow-up at the time of the study.
The clinical, radiographic characteristics, treatment methods and outcomes of the bilateral IVADA cases are summarised in tables 1–3. The mean age of the 27 patients (4 women and 23 men) was 54.26±6.22 years (mean±SD). Six patients (22.2%) presented with incidental findings; 16 patients (59.3%) presented with different symptoms (11 with headache, 4 with dizziness, 1 with numbness of limbs). All IVADAs were successfully treated with endovascular treatment. Thirty-six IVADAs (85.7%) have complete obliteration at the follow-up angiography, and two IVADAs (4.8%) recanalised which had further retreatment. Three patients (11.1%) have intraprocedural or postprocedural complications. None had bleeding or rebleeding during the clinical follow-up. Twenty-five patients (92.6%) had a favourable clinical outcome at the follow-up, and two patients (7.4%) showed an unfavourable clinical outcome at the last follow-up. According to the treatment method used, the included patients were divided into three categories, namely (1) single-stage, (2) staged and (3) unilateral endovascular treatment.
Single-stage endovascular treatment
Four patients received single-stage endovascular treatment (table 1). Seven IVADAs (87.5%) have complete obliteration at the follow-up angiography, and one IVADA (12.5%) in a patient with SAH recanalised at the 3-month follow-up. Both IVADAs of the patient with SAH were treated with SAC, for which a CT scan was unable to determine the ruptured side. At first follow-up, the right IVADA was stable, the recanalised left IVADA was treated again with coiling. Both IVADAs were complete obliteration at the final follow-up angiography (figure 2). Two patients (50%) had complications, and had unfavourable results at last follow-up. One patient was treated with trapping of the right IVADA and SAC of the left side. The patient displayed muscle weakness in their right limbs 3 days after treatment, and the postprocedure MRI showed cerebellar infarction. One patient with SAC of both IVADAs did not fully comply with the medical advices at 2 months postprocedure, and stop taking prescribed antiplatelet medications. The patient showed sudden unconsciousness (mRS=5). The MRI showed cerebellar infarction and stenosis of the vertebrobasilar artery. The patient received tissue-type plasminogen activator thrombolysis intravenously, and recovered to consciousness (mRS=4). The mRS score of both patients was 3 at last follow-up.
Staged endovascular treatment
Twelve patients received staged endovascular treatment, and showed in table 2. Twenty IVADAs (83.3%) have complete obliteration at the follow-up angiography. One ruptured IVADA (4.2%) recanalised, and had retreatment. It remained stable at further follow-up. The unruptured IVADA of the patient was treated staged within 1 month, and showed complete obliteration at the final follow-up. For the 11 unruptured patients, 13 IVADAs (59.0%) were reconstructed with traditional stent, and nine IVADAs were reconstructed with flow diverter (41.0%). Complete obliteration rate was achieved 100% in IVADAs with flow diverter and 76.9% in IVADAs with traditional stent at follow-up angiography. Eleven IVADAs (50.0%) involved the origin of PICA, six IVADAs were with flow diverter. One complication occurred in the patient of IVADA involved PICA with flow diverter, the parent artery showed stenosis after flow diverter, and occluded at follow-up period. However, no clinical symptoms occurred, for which the PICA received compensatory blood flow from the other VA (figure 3). All patients (100%) had favourable clinical outcome at the follow-up.
Only one side of bilateral IVADAs with endovascular treatment
Eleven patients received only unilateral endovascular treatment, and showed in table 3. One patient had a ruptured IVADA and a Hunt-Hess grade of 1, and three had IVADAs involving the origin of PICA. Four IVADAs (36.4%) were reconstructed with flow diverter. At follow-up angiography, complete obliteration was achieved in all IVADAs (100%) with flow diverter, and the complete obliteration rate was 71.4% in six IVADAs with SAC for that one patient refused to return for the invasive inspection. No procedure-related complications occurred, and all patients had favourable clinical outcome during the follow-up period. One tandem IVADA had complete obliteration after flow diverter, and the contralateral untreated IVADA were stable on follow-up angiography (figure 4).
Comparison of three different treatments in patients with unruptured bilateral IVADAs
We compared the treatments in patients with bilateral IVADAs, obviously significant difference was showed in treatment methods (table 4). Importantly, the patients with staged treatment and one side reconstructive treatment had significant lower thromboembolic complication rate compared with the patients with single-stage treatment (p<0.01 for both comparisons). At admission, the mRS score had no difference between three methods. However, for the last mRS score, the patients with staged treatment and one side reconstructive treatment were significantly lower than that with single-stage treatment (p<0.01 for both comparisons).
Of the patients who received the single-stage endovascular treatment, one had a cerebellar infarction, and insufficient compensatory blood flow might be the reason. Moreover, urgent in-stent thrombosis was observed in an uncomplied patient. Both of the patients have unfavourable outcomes at last follow-up. Similarly, one patient with staged treatment had parent artery occlusion at follow-up, but no clinical symptoms occurred. In the patients receiving staged or unilateral endovascular treatment, all IVADAs were reconstructed using stent alone, using SAC or flow diverter, and no growth and ruptured IVADAs occurred at follow-up. These results may indicate that the haemodynamic alteration of the contralateral VA was slight after unilateral reconstructive endovascular treatment, and as such, did not lead to contralateral IVADA enlargement and possible rupture. Compared with the three methods, the patients with staged treatment and one side reconstructive treatment had significant lower thromboembolic complication rate and mRS score compared with the patients with single-stage treatment. Such results might demonstrate that the application of staged reconstructive endovascular treatment in patients with unruptured bilateral IVADAs might decrease the risk of thromboembolic events and led to favourable outcomes. For the ruptured IVADAs, the best treatment might be parent artery occlusion, for which a lower recanalisation rate was shown. However, trapping the parent artery increased haemodynamic stress on the contralateral VA, leading to enlargement and possibly to rupture. In this study, a reconstructive treatment was performed on three ruptured IVADAs, of which two were recanalised. A close follow-up and treatment again with coiling might be important for such aneurysms.
Endovascular treatment of bilateral IVADAs presenting with SAH
IVADA presenting with SAH has been reported to occur in approximately 3% of all cases of SAH. As this condition has been known to cause a high rate of rebleeding, prompt non-reconstructive treatment procedures, such as proximal occlusion or trapping, are advocated to prevent this.6 11 Open surgical intervention might be not a good option for acute dissecting aneurysms of the VA, given the rather high risks of treatment-related morbidity and mortality; endovascular non-reconstructive treatment is the standard procedure.12 However, if the contralateral VA shows hypoplasia or occlusion, or if the IVADA itself is of the PICA-involved type, proximal occlusion or trapping are inadequate. In this case, open surgical might also be considered even though it is invasive and technically difficult. Saito et al 13 and Ota et al 14 reported that bypass of arteries for the bilateral IVADAs was an effective method to preserve the perforators and provide blood flow. Furthermore, trapping the VA places increased haemodynamic stress on the contralateral VA, which might lead to enlargement and possibly rupture.15 16 Therefore, revascularisation of the parent (ipsilateral) artery territory can be performed to preserve ipsilateral VA flow.17–19 In our study, three patients with SAH were treated with parent artery reconstruction, while two IVADAs recanalised at follow-up. Such recanalised IVADAs were also reported to have a high rate of rebleeding associated with high risk of morbidity and mortality. For the recanalised IVADAs in this study, patients were treated again with coiling and complete obliteration was found at follow-up.
Detection of the ruptured side is not easy in cases of bilateral IVADAs presenting with SAH.18 The following determinants have been identified in prior reports: the headache side;20 hemiplegia;21 a thicker haematoma on a CT image;22 23 a larger and more irregular aneurysm;21 22 the pearl-and-string sign;21 a pooling of contrast media in a pseudoaneurysm on angiography22 23 and an intramural haematoma on MR images.24 If the ruptured side is not clearly verified, bilateral, single-stage treatment should be performed to avoid the misidentified lesion being untreated. In our study, the laterality of the SAH on CT scans and the pooling of the contrast agent on the cerebral angiography clearly showed the ruptured side in two cases. However, in one case, the ruptured side could not be determined, and we reconstructed the bilateral IVADAs in a single stage; fortunately, no procedure-related complication occurred in this patient. Thus, in our patients, we first determined the ruptured side of the IVADA based on the laterality of the SAH on CT scans. Reconstructive endovascular treatment was our first choice for a ruptured IVADA with a dominant VA or with involvement of the PICA, while non-reconstructive endovascular treatment, such as proximal occlusion or trapping, was performed for a ruptured IVADA without these characteristics. For confirmed cases of a ruptured IVADA, endovascular treatment of bilateral IVADAs should be performed, and staged reconstructive endovascular treatment should be performed for an unruptured IVADA.
Single-stage or staged endovascular treatment for bilateral IVADAs?
With recent advances in device technologies, endovascular treatment has become the first-line treatment for VA dissecting aneurysms. Reconstructive endovascular treatment preserves bilateral VA flow, while treatment by stent placement can ensure preservation of the VA. Stent-assisted coil embolisation is better than stent-alone therapy for promoting faster thrombosis, and it is simpler and more acceptable for treating both aneurysms in a single session than trapping, because it does not require a balloon occlusion test and can be performed on patients with no tolerance. In addition, single-stage endovascular treatment has potential advantages, in which dual antiplatelet therapy is mandatory. Securing all aneurysms theoretically decreases the fatal bleeding risk in case of rupture of the unsecured aneurysms. The duration of antiplatelet therapy is reduced in single-stage treatment compared with staged procedures. However, the use of stents or flow diverters increases the risk of thromboembolic events. In particular, in patients with bilateral IVADAs, single-stage treatment with flow diverters carries the potential risk of simultaneous stent thrombosis, which may cause morbidity and mortality by blocking the collateral pathways. Wilkinson et al 25 reported staged endovascular treatment of bilateral IVADAs with SAH, in which the IVADAs were treated successfully by staged SAC. First, a ruptured IVADA was treated, followed by subsequent treatment of the contralateral unruptured IVADA; no thromboembolic events occurred. Moreover, Andic et al 26 also found that staged treatment might be used instead of single-stage treatment to avoid thromboembolic events in the patients with bilateral intracranial aneurysms. In the current study, two patients with bilateral IVADAs were treated simultaneously in a single stage, and have unfavourable clinical outcomes. One patient showed cerebellar infarction after treatment, and another patient have urgent in-stent thrombosis. Conversely, delayed mechanical stent occlusion caused the loss of the parent artery in a patient with staged treatment. No clinical symptoms were found during the follow-up period. Staging of endovascular treatment in this group of patients may be a reasonable choice in order to avoid thromboembolic events, despite leaving an aneurysm unsecured under dual antiplatelet therapy.
Era of reconstructive endovascular treatment for bilateral IVADAs
To reduce unpredictable haemodynamic stress on the contralateral aneurysm, revascularisation of the parent (ipsilateral) artery territory is desirable. Endovascular techniques like flow-diverting stents have been used successfully to preserve the VA. In a recent study, Park et al 17 reported that stent-only therapy using single, double or triple overlapping stents was safe and effective for the treatment of IVADAs. In addition, multiple-overlapping, but not single, stent therapy, resulted in angiographic improvement.19 Stent application over the dissecting segment, especially with multiple overlapping stents, can lead to haemodynamic changes (decreases in inflow complexity, momentum, velocity and wall shear stress), whereas intra-aneurysmal blood turnover time is increased.27 28
Flow diverters have emerged as an attractive treatment option for these challenging lesions. These devices are placed in the parent artery and affect the haemodynamics such that there is an eventual remodelling of the affected segment via endothelial proliferation. Originally, flow diverters were used to treat wide-necked aneurysms of the anterior circulation.29 However, as interventionalists have become more experienced and comfortable with flow diverters, these devices have shown benefits for posterior circulation dissecting aneurysms and have yielded favourable outcomes.30 31 However, the use of flow diverters on the VA system is not without risks. In-stent thrombosis and thromboembolic events are feared complications, with up to 52% of patients showing changes on MR diffusion-weighted imaging scans and up to 14% experiencing symptomatic infarctions.32 Occlusion of perforators can occur acutely by direct mechanical blockage from a tine or strut of the flow diverter, by a thrombus from the device migrating to the branching artery, or chronically by excessive neointimal proliferation (ie, in-stent stenosis). The use of antiplatelet medications, close monitoring of platelet function with medication and dose adjustments based on response are important considerations for flow diverter placement.
As in our patient, reconstructive endovascular treatment can be used to exclude the IVADAs without obstructing their flow. This thereby avoids a dramatic increase in flow and haemodynamic stress in the contralateral IVADAs, which would otherwise likely contribute to high mortality. Ishikawa et al 33 reported a bilateral IVADAs case with SAH that the ruptured side was well treated with SAC, and the contralateral side was stable at follow-up after treatment. Such results might also support that reconstructive endovascular treatment has little impact on the haemodynamic stress to the contralateral IVADA. The staged reconstructive endovascular treatment of bilateral IVADAs appears to be an efficacious approach. Although in our patient the second IVADA was repaired one month after the first, the optimal timing for staged bilateral repair remains uncertain. Even stent-based therapy, however, causes some alteration in flow that may predispose the enlargement of a previously existing contralateral pseudoaneurysm, or even the formation of a new contralateral pseudoaneurysm.34 For this reason, follow-up shortly after the initial repair is important in order to be able to promptly recognise any alteration in the contralateral VA and to intervene prior to any catastrophic event.
Our study has several limitations, the study was a retrospective study over a long time-period, so that might include some confounding factors, such as patient selection and treatment technique bias. Bilateral IVADAs are rare entities, and this study enrolled only 25 such cases. Finally, given the rarity of bilateral IVADAs, the timespan over which the endovascular treatment occurred was long, and the methods used for the treatment were diverse are also limitations.
The endovascular treatment protocol for bilateral IVADAs proposed in this study might be helpful in the management of this rare lesion. The endovascular treatment was safe and effective, and led to favourable outcomes for bilateral IVADAs. Application of staged reconstructive endovascular treatment might decrease the risk of thromboembolic events, and of contralateral IVADA growth and rupture. Flow diverters might enable a higher rate of complete occlusion embolisation for this rare lesion, while occlusion of the parent artery should also be considered.
Contributors WL performed the statistical analysis and the manuscript writing. WL, ZT, WZ, JL and KW acquired the data. WL, YisZ, YinZ and YW contributed to data analysis and interpretation. YisZ and XY contributed to the experimental design and manuscript revision, and handled funding and supervision. YisZ and XY were the co-corresponding authors.
Funding This study was funded by National Natural Science Foundation of China (81220108007, 81801156, 81801158, 81471167 and 81671139); Beijing Hospitals Authority Youth Programme (QML20190503); Special Research Project for Capital Health Development (2018-4-1077); National Key Research and Development Plan of China (2016YFC1300800); Innovation Fund of Nanchang University for Graduate Students (cx2016312).
Competing interests None declared.
Patient consent for publication Obtained.
Ethics approval The Ethics Committee of our hospital approved this retrospective study.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement No data are available.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.